| 余丽蕾.温肺健脾汤治疗支气管哮喘慢性持续期患者临床疗效及对细胞因子、TGF-β1和VEGF水平的影响[J].浙江中西医结合杂志,2022,32(8): |
| 温肺健脾汤治疗支气管哮喘慢性持续期患者临床疗效及对细胞因子、TGF-β1和VEGF水平的影响 |
| Clinical effect of Wenfei Jianpi Decoction on chronic persistent bronchial asthma and its influence on the levels of cytokines, TGF-β1 and VEGF、 |
| 投稿时间：2021-07-16 修订日期：2022-07-18 |
| DOI： |
| 中文关键词: 温肺健脾汤 支气管哮喘 慢性持续期 疗效 细胞因子 转化生长因子-β1 血管内皮生长因子 |
| 英文关键词:Wenfei Jianpi Decoction bronchial asthma chronic duration curative effect cytokines transforming growth factor-β1 vascular endothelial growth factor |
| 基金项目: |
|
| 摘要点击次数: 611 |
| 全文下载次数: 11 |
| 中文摘要: |
| 目的：探讨温肺健脾汤治疗支气管哮喘(哮喘)慢性持续期患者临床疗效及对细胞因子、转化生长因子-β1(TGF-β1)和血管内皮生长因子(VEGF)影响。方法：选择我院于2019年1月~2020年6月哮喘慢性持续期患者102例,按照随机数字法分为治疗组与对照组,各51例。对照组采用常规西医治疗,治疗组在对照组基础上口服温肺健脾汤。两组疗程12周。比较两组治疗12周总有效率；治疗前与治疗12周肺功能、日间和夜间喘息症状,细胞因子,转化生长因子-β1(TGF-β1)和血管内皮生长因子(VEGF)变化,及不良反应。结果：治疗12周,治疗组总有效率94.12%(48/51),高于对照组72.55%(37/51)(P<0.05)。治疗12周,两组PEF%和FEV1%高于治疗前(P<0.05)；治疗12周,治疗组PEF%和FEV1%高于对照组(P<0.05)。治疗12周,两组日间和夜间喘息症状积分高于治疗前(P<0.05)；治疗12周,治疗组日间和夜间喘息症状积分高于对照组(P<0.05)。治疗12周,两组血清IL-4和IL17水平低于治疗前而IL-10水平高于治疗前(P<0.05)；治疗12周,治疗组血清IL-4和IL17水平低于对照组而IL-10水平高于对照组(P<0.05)。治疗12周,两组血清TGF-β1和VEGF水平低于治疗前(P<0.05)；治疗12周,治疗组血清TGF-β1和VEGF水平低于对照组(P<0.05)。两组治疗期间无明显不良反应。结论：温肺健脾汤治疗哮喘慢性持续期患者疗效明显,且可调节细胞因子水平,降低TGF-β1和VEGF水平。 |
| 英文摘要: |
| Objective: To investigate the clinical effect of Wenfei Jianpi Decoction on chronic persistent bronchial asthma and its influence on the levels of cytokines, transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF). Methods: The 102 patients with chronic persistent asthma in our hospital from January 2019 to June 2020 were randomly divided into treatment group and control group, 51 cases in each group. The control group was treated with conventional western medicine, and the treatment group was treated with Wenfei Jianpi Decoction on the basis of the control group. The course of treatment was 12 weeks. The total effective rate, lung function, daytime and nighttime wheezing symptoms, cytokine, TGF-β1 and VEGF, changes, and adverse reactions were compared between the two groups. Results: after 12 weeks of treatment, the treatment group effective rate was 94.12% (48/51), which higher than control group 72.55% (37/51) (P<0.05). After 12 weeks of treatment, the two groups PEF% and FEV1% higher than before treatment (P<0.05); after 12 weeks of treatment, the treatment group PEF% and FEV1% higher than control group (P<0.05). After 12 weeks of treatment, the two groups scores of day night and night wheezing symptoms higher than before treatment (P<0.05); after 12 weeks of treatment, the treatment group scores of day night and night wheezing symptoms higher than control group (P<0.05). After 12 weeks of treatment, the two groups serum IL-4 and IL-17 lower than before treatment, but the level of IL-10 higher than before treatment (P<0.05); after 12 weeks of treatment, the treatment group serum IL-4 and IL-17 lower than control group, but the level of IL-10 higher than control group (P<0.05). After 12 weeks of treatment, the serum levels of TGF-β1 and VEGF in the two groups were lower than those before treatment (P<0.05); after 12 weeks of treatment, the serum levels of TGF-β1 and VEGF in the treatment group were lower than those in the control group (P<0.05). There was no obvious adverse reaction in the two groups. Conclusion: Wenfei Jianpi Decoction is effective in treating chronic persistent asthma, and can regulate the level of cytokines, decreased levels of TGF-β1 and VEGF. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
